

Product Datasheet

Order: order@ebiocell.com

TEL: (540)808-3925

Supprt: tech@ebiocell.com
Web: www.ebiocell.com

CD19 Rabbit Polyclonal Antibody

Catalog #: EAB10676

Host/Isotype	Clonality	Applications	MW (kDa)	Reactivity
Rabbit IgG	Polyclonal	WB, IHC-P, IF/ICC, FC, ELISA	61	Human, Mouse, Rat

Applications Dilutions

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

WB(Western Blotting) 1:500-2000
IHC-P(Immunohistochemistry-Paraffin) 1:50-300
IF/ICC(Immunofluorescence/Immunocytochemistry) 1:50-300
FC(Flow Cytometry) 1:50-200
ELISA(Enzyme-linked Immunosorbent Assay) 1:5000-20000

Product Information

Conjugate Unconjugate

Specificity CD19 Rabbit Polyclonal Antibody detects endogenous levels of CD19 protein.

Purification Affinity purification

Concentration1mg/mlFormatLiquid

Formulation In PBS, pH 7.4, Containing 0.02% sodium azide, 0.5% BSA and 50% Glycerol

Shipping Gel Pack

Storage Storag

Aliquots may be stored at +4°C for 1-2 weeks

 UniProt ID
 P15391

 Entrez-Gene Id
 930

Product Description

This gene encodes a member of the immunoglobulin gene superfamily. Expression of this cell surface protein is restricted to B cell lymphocytes. This protein is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. The protein has two N-terminal extracellular Ig-like domains separated by a non-Ig-like domain, a hydrophobic transmembrane domain, and a large C-terminal cytoplasmic domain. This protein forms a complex with several membrane proteins including complement receptor type 2 (CD21) and tetraspanin (CD81) and this complex reduces the threshold for antigen-initiated B cell activation. Activation of this B-cell antigen receptor complex activates the phosphatidylinositol 3-kinase signalling pathway and the subsequent release of intracellular stores of calcium ions. This protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of lymphoblastic leukemia. Mutations in this gene are associated with the disease common variable immunodeficiency 3 (CVID3) which results in a failure of B-cell differentiation and impaired secretion of immunoglobulins. CVID3 is characterized by hypogammaglobulinemia, an inability to mount an antibody response to antigen, and recurrent bacterial infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms.